{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.78","value":"57.28"},{"groupId":"OG002","spread":"18.79","value":"69.59"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"32"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG002","spread":"88.94","value":"175.73"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.41","value":"105.14"},{"groupId":"OG002","spread":"69.74","value":"193.38"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG002","spread":"58.38","value":"208.14"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"Cycle 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.79","value":"227.75"},{"comment":"Not calculable with only 1 participant","groupId":"OG001","spread":"NA","value":"206.00"},{"groupId":"OG002","spread":"70.06","value":"193.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"Cycle 7"},{"categories":[{"measurements":[{"comment":"Not calculable with only 1 participant","groupId":"OG001","spread":"NA","value":"206.00"},{"groupId":"OG002","spread":"38.20","value":"212.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"Cycle 11"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"41"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"description":"Serum concentration achieved at the end of study drug infusion","dispersionType":"Standard Deviation","groups":[{"description":"ND Regimen\n\nEach cycle is 28 days\n\nNivolumab:\n\nCycle 1: 240 mg iv Day 15 Cycle 2-6: 240 mg iv Days 1, 15 Cycle 7 \\& beyond: 480 mg iv Day 1\n\nDaratumumab:\n\nCycle 1-2: 16 mg/kg iv Days 1, 8, 15, 22 Cycle 3-6: 16 mg/kg iv Days 1, 15 Cycle 7 \\& beyond: 16 mg/kg iv Day 1\n\nPomalidomide:\n\n4 mg po daily (Days 1-21) of each 28-day cycle\n\nDexamethasone:\n\nWeeks without daratumumab dosing 40 mg po per day (Days 1, 8, 15, 22) of each 28-day cycle for subjects 75 years old 20 mg po per day (Days 1, 8, 15, 22) of each 28-day cycle for subjects \\> 75 years old","id":"OG000","title":"Cohort A-1"},{"description":"ND-Pd Regimen\n\nEach cycle is 28 days\n\nNivolumab:\n\nCycle 1: 240 mg iv Day 15 Cycle 2-6: 240 mg iv Days 1, 15 Cycle 7 \\& beyond: 480 mg iv Day 1\n\nDaratumumab:\n\nCycle 1-2: 16 mg/kg iv Days 1, 8, 15, 22 Cycle 3-6: 16 mg/kg iv Days 1, 15 Cycle 7 \\& beyond: 16 mg/kg iv Day 1","id":"OG001","title":"Cohort A-2"},{"description":"ND Regimen\n\nEach cycle is 28 days\n\nNivolumab:\n\nCycle 1: 240 mg iv Day 15 Cycle 2 \\& beyond: 480 mg iv Day 1\n\nDaratumumab:\n\nCycle 1\\*-2: 16 mg/kg iv Days 1, 8, 15, 22 Cycle 3-6: 16 mg/kg iv Days 1, 15 Cycle 7 \\& beyond: 16 mg/kg iv Day 1","id":"OG002","title":"Cohort B-1"},{"description":"D Monotherapy Regimen\n\nEach cycle is 28 days\n\nDaratumumab:\n\nCycle 1\\*-2: 16 mg/kg iv Days 1, 8, 15, 22 Cycle 3-6: 16 mg/kg iv Days 1, 15 Cycle 7 \\& beyond: 16 mg/kg iv Day 1","id":"OG003","title":"Cohort B-2"}],"paramType":"MEAN","populationDescription":"All treated participants in the nivo dara cohort - pharmacokinetic subset","reportingStatus":"POSTED","timeFrame":"Measurements collected at cycles 1, 2, 3, 5, 7, and 11; each cycle is 28 days","title":"End of Infusion Nivolumab Concentration Levels in the Nivolumab + Daratumumab Cohort","type":"SECONDARY","unitOfMeasure":"ug/mL"}